Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
By J. Vredenburgh, A. Desjardins, J. Herndon, J. Marcello, D. Reardon, J. Quinn, Jeremy N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson and 5 more. Journal of Clinical Oncology, 2007
1,395 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/f717968ca5d8393e3c478c6e87aaf86027436107
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Glioblastoma survival in the United States before and during the temozolomide era (2012, background): “Additionally, the potentially confounding effect of bevacizumab salvage therapy was addressed by comparing survival of patients diagnosed in 2000–2003 with patients diagnosed in 2005 only, the significant majority of whom would have succumbed to glioblastoma before bevacizumab became widely used for”
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma (2011, neutral): “Acta Neurochir (Wien) 140(6):607–612; discussion 612–603.”
- The Hypoxic Microenvironment Maintains Glioblastoma Stem Cells and Promotes Reprogramming towards a Cancer Stem Cell Phenotype (2009, background): “Targeted therapies have largely failed in clinical trial with the notable exception of bevacizumab (Avastin), a neutralizing antibody against vascular endothelial growth factor (VEGF).(3,4) Despite substantial research efforts, the mechanisms underlying the overwhelming lethality of glioblastomas re”